Cullgen: Funding, Investors & Team (Sep 2026)
Cullgen aims to generate previously non-existent remedies for illnesses that cannot be treated effectively by discovering new drugs. To fulfill this objective, the company harnesses protein degradation technology that removes harmful proteins related to cancer, inflammatory, and autoimmune illnesses. With this approach, Cullgen can tackle conditions that were previously deemed impossible to combat, providing scientists with unique techniques to formulate treatments for diverse ailments.
Cullgen has raised $35.0M across 1 funding round on record, the most recent a Series C of $35.0M announced in May 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cullgen Company Profile and Key Stats
Latest funding round on record: May 2023.
Cullgen Funding Rounds
Cullgen Founders and Leadership Team
Contact details for the Cullgen team: 1 of 1 has an email address on file.
Start 14-day free trial →Cullgen Funding Compared to Other Biotechnology Startups
Cullgen's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cullgen in Biotechnology and San Diego
Companies Similar to Cullgen
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Cullgen Funding FAQs
What does Cullgen do?
Cullgen aims to generate previously non-existent remedies for illnesses that cannot be treated effectively by discovering new drugs. To fulfill this objective, the company harnesses protein degradation technology that removes harmful proteins related to cancer, inflammatory, and autoimmune illnesses. With this approach, Cullgen can tackle conditions that were previously deemed impossible to combat, providing scientists with unique techniques to formulate treatments for diverse ailments.
How much funding has Cullgen raised?
Cullgen has raised $35.0M across 1 round on record. The most recent is a Series C of $35.0M announced in May 2023.
When did Cullgen last raise funding?
Cullgen's most recent funding round on record is a Series C of $35.0M, announced in May 2023.
Who founded Cullgen?
FundedIQ lists Yue Xiong (Founder) at Cullgen.
Where is Cullgen headquartered?
Cullgen is based in San Diego, California, United States.
How many employees does Cullgen have?
Cullgen is in the 11-50 employee band.
How does Cullgen's funding compare to other Biotechnology startups?
Cullgen's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Cullgen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cullgen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.